BiotechTube

NVG-291

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Spinal Cord Injuries

Conditions

Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury

Trial Timeline

Aug 8, 2023 → Apr 1, 2026

NCT ID
NCT05965700

About NVG-291

NVG-291 is a phase 1/2 stage product being developed by NervGen Pharma for Spinal Cord Injuries. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05965700. Target conditions include Spinal Cord Injuries, Chronic Spinal Cord Injury, Subacute Spinal Cord Injury.

What happened to similar drugs?

7 of 20 similar drugs in Spinal Cord Injuries were approved

Approved (7) Terminated (1) Active (12)
🔄Ropivacaine + BupivacaineAstraZenecaPhase 3
🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3
✅Onasemnogene Abeparvovec-brveNovartisApproved
🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3
🔄Onasemnogene Abeparvovec-xioiNovartisPhase 3
🔄onasemnogene abeparvovecNovartisPhase 3
🔄onasemnogene abeparvovec-xioiNovartisPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
5
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05965700Phase 1/2Recruiting
NCT05308953Phase 1Completed

Competing Products

20 competing products in Spinal Cord Injuries

See all competitors
ProductCompanyStageHype Score
SUN13837 injection + PlaceboDaiichi SankyoPhase 2
35
Placebo + Reldesemtiv 150 mg + Reldesemtiv 450 mgAstellas PharmaPhase 2
35
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 2
42
Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor CellsSun PharmaceuticalPhase 1
36
ElezanumabAbbViePre-clinical
30
Elezanumab + PlaceboAbbViePhase 2
35
Ropivacaine + BupivacaineAstraZenecaPhase 3
40
Onasemnogene Abeparvovec-xioiNovartisPhase 1
21
ZolgensmaNovartisPre-clinical
33
BVS857 + PlaceboNovartisPhase 2
35
AVXS-101NovartisPhase 1
29
Onasemnogene Abeparvovec-xioiNovartisPhase 3
44
Onasemnogene Abeparvovec-brveNovartisApproved
50
Onasemnogene Abeparvovec-xioiNovartisPre-clinical
30
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
branaplamNovartisPhase 1/2
32
Onasemnogene Abeparvovec-xioiNovartisPhase 3
40
onasemnogene abeparvovecNovartisPhase 3
47
onasemnogene abeparvovec-xioiNovartisPhase 3
40
RisdiplamRochePhase 1
29